Tradestie Institutional Equity Comparison Engine

CLDX vs RAPT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RAPT Overall Edge

RAPT Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to RAPT Therapeutics, Inc. Common Stock (RAPT) driven by superior Momentum & Technical, Options & Structure while CLDX counters with relative strength in Growth & Margin. Fundamentally, CLDX trades at N/M Forward P/E with -211684.8% operating margin (-97.0% YoY revenue) versus RAPT at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, CLDX sits in BREAKDOWN (56th %ile IV; Dealer Gamma Walls on Pro) against RAPT sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CLDX N/M vs RAPT N/M Fwd P/E
Growth & Margin Winner CLDX
Op Margin -211684.8% vs 0.0% ยท YoY -97.0% vs -100.0%
Momentum & Technical Winner RAPT
1Y +21.1% vs +480.2% ยท 52W Pos 28% vs 100%
Options & Structure Winner RAPT
BREAKDOWN (56th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
CLDX NASDAQ
Celldex Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$28.71
-0.4% 1D
Market Cap $2.2B
1M Return +4.3%
1Y Return +21.06%
Forward P/E N/M
Unified AI Score
55.7 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 65.0 Mom 50.0
RAPT NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
1M Return +0.68%
1Y Return +480.2%
Forward P/E N/M
Unified AI Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLDX +21.06% RAPT +480.2% Spread: +84.53 pp (RAPT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLDX TTM Op. Margin: -211684.8% RAPT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLDX vs RAPT. Trailing 12-month operating profitability (CLDX -211684.8% vs RAPT 0.0%) and valuation multiples (CLDX N/M vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLDX (4) vs RAPT (3)
Institutional Metric CLDX RAPT Criterion Row Winner
Market Capitalization Scale $2.2B $1.7B Larger Scale CLDX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -97.0% -100.0% Higher Growth CLDX
Operating Margin (TTM) Profitability -211684.8% 0.0% Higher Margin RAPT
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -49.5% -85.4% Higher ROE CLDX
52-Week Range Position Momentum 28% ($22โ€“$45) 100% ($1โ€“$58) Stronger Trend RAPT
Beta / 30D Volatility Risk Regime 1.06ฮฒ ยท 46% Vol -0.02ฮฒ ยท 2% Vol Lower Realized Risk RAPT
Unified Institutional Score Composite Signal 55.7 / 100 (HOLD) 52.4 / 100 (HOLD) Higher Composite CLDX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLDX vs RAPT Buy Guide
CLDX BREAKDOWN
67d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 56th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CLDX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RAPT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live RAPT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLDX nor RAPT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.